Overview
The Brazilian Health Regulatory Agency (ANVISA) recently published an official clarification regarding the unification of petition subject codes used for submissions related to the Certificate of Good Manufacturing Practices (CBPF) for medical devices.
Introduction
This initiative aims to simplify and streamline the regulatory petition process, reducing unnecessary complexity while maintaining full compliance with the requirements established under RDC No. 497/2021.
Importantly, ANVISA emphasized that this administrative change does not alter the regulatory effects, obligations, or technical requirements already defined by the existing legislation.
This blog explores what has changed, what remains the same, and the practical impact of this update for manufacturers and regulatory professionals operating in Brazil.
What is CBPF and Why is it Important
The Certificate of Good Manufacturing Practices (CBPF) is an official document issued by ANVISA confirming that a manufacturing site complies with Brazil’s Good Manufacturing Practices requirements
For medical device manufacturers, CBPF plays a critical role in:
- Supporting product registration and market authorization
- Demonstrating compliance with quality management standards
- Strengthening credibility with international partners and regulatory authorities
CBPF is often a prerequisite for companies seeking access to Brazil’s highly regulated healthcare market.
Unification of Petition Subject Codes
Traditionally, different categories of medical devices and in vitro diagnostic products required companies to submit CBPF-related petitions using multiple distinct subject codes within ANVISA’s electronic submission platform (Solicita).
To improve regulatory efficiency, ANVISA has now implemented the unification of these subject codes, consolidating them into a more standardized and simplified structure.
The main objectives of this unification include:
- Reducing confusion during submission
- Minimizing administrative errors
- Improving internal workflow organization
- Enhancing the overall efficiency of CBPF petition handling
This change reflects ANVISA’s broader efforts toward regulatory modernization and process optimization.
What Remains Unchanged Under RDC 497/2021
ANVISA clearly stated that the unification of subject codes does not modify the regulatory framework established by RDC No. 497/2021, which governs CBPF procedures for medical devices.
Key requirements remain the same, including
Separate CBPF petitions must still be submitted for:
- Medical materials and equipment
- In vitro diagnostic products (IVDs)
Previously submitted petitions will not be affected, even if filed under the older subject codes.
Therefore, this is strictly an administrative simplification rather than a regulatory change in substance.
Practical Impact for the Regulated Industry
For manufacturers, regulatory consultants, and compliance teams, the consolidation of subject codes is expected to bring several benefits:
- Greater clarity during petition preparation
- Reduced risk of selecting incorrect submission categories
- Improved usability of ANVISA’s Solicita platform
- Faster adaptation to standardized regulatory workflows
Industry associations have recognized this measure as a step toward reducing regulatory barriers while preserving robust GMP oversight.
Companies should nevertheless ensure that internal regulatory procedures are updated accordingly, particularly when preparing new CBPF submissions.
Conclusion
ANVISA’s clarification regarding the unification of petition subject codes for CBPF submissions represents an important administrative improvement for the Brazilian medical device regulatory environment.
By simplifying the submission structure without changing the legal or technical requirements of RDC 497/2021, ANVISA reinforces its commitment to regulatory efficiency, transparency, and modernization.
For stakeholders, this update should be viewed as a positive step toward more streamlined interactions with the agency, supporting compliance while reducing unnecessary complexity in the CBPF petition process.
GRP Brazil
If you are interested in registering your products in Brazil, GRP is ready to help. Our team of experts can simplify the process of registering products in Brazil and make it easier to schedule meetings with Anvisa more efficiently.
GRP can act as your local Agent & Register your product in U.S
Contact our team today to Inquire!
Email: info@globalregulatorypartners.com
Telephone : (+1) 781-672-4200
References
Learn more about Anvisa.
- ANVISA – Official clarification on the unification of petition subject codes for CBPF, without altering the effects of RDC 497/2021.
- ANVISA – Announcement on the unification of CBPF petition subject codes for medical devices.
- Brazilian government dataset – Overview of CBPF certificates and GMP regulatory framework.
- CBDL – Sector analysis on ANVISA’s unification of certification codes and reduction of regulatory barriers.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations.